QIPB vs SI-FICB for Postoperative Analgesia After Total Hip Arthroplasty
Comparison of Quadro-Iliac Plane Block and Supra-Inguinal Fascia Iliaca Compartment Block for Postoperative Analgesia in Total Hip Arthroplasty: A Prospective, Double-Blind, Non-Inferiority Study
1 other identifier
interventional
84
1 country
1
Brief Summary
Total hip arthroplasty (THA) causes moderate-to-severe postoperative pain. The PROSPECT guideline recommends the supra-inguinal fascia iliaca compartment block (SI-FICB) for THA, whereas evidence for newer quadratus-lumborum-family blocks is limited. The quadro-iliac plane block (QIPB) is a recently described fascial plane block, and no study has compared QIPB with SI-FICB head-to-head in any surgical context. In this prospective, double-blind, patients undergoing elective THA who receive one of the two routinely used preoperative blocks (SI-FICB or QIPB, chosen by the attending anesthesiologist as part of routine care) are systematically observed and compared. The primary objective is to assess whether the postoperative analgesic efficacy of QIPB is non-inferior to SI-FICB, using the resting NRS pain score at 6 hours postoperatively as the primary endpoint (non-inferiority margin Δ = 1.3).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Jun 2026
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 23, 2026
CompletedStudy Start
First participant enrolled
June 30, 2026
CompletedFirst Posted
Study publicly available on registry
July 6, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
June 1, 2027
July 6, 2026
June 1, 2026
5 months
June 23, 2026
June 27, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Pain intensity at rest at 6 hours postoperatively
Numeric Rating Scale (NRS), 0 = no pain to 10 = worst imaginable pain, measured at rest by a blinded assessor. Non-inferiority margin Δ = 1.3 NRS points.
6 hours after surgery
Secondary Outcomes (3)
NRS pain at rest
0, 2, 4, 6, 12, 24, 48 hours postoperatively
NRS pain on movement (active hip flexion)
0, 2, 4, 6, 12, 24, 48 hours postoperatively
Cumulative opioid consumption
24 hours and 48 hours
Study Arms (2)
SI-FICB
ACTIVE COMPARATORPatients receiving supra-inguinal fascia iliaca compartment block (single-shot, US-guided, 40 mL 0.25% bupivacaine, preoperative).
QIPB
EXPERIMENTALPatients receiving quadro-iliac plane block (single-shot, US-guided, 40 mL 0.25% bupivacaine, preoperative).
Interventions
SIFICB is an ultrasound-guided fascial plane block performed via a supra-inguinal approach to the iliac fascia compartment, targeting the femoral nerve, lateral femoral cutaneous nerve, and obturator nerve. Single-shot, US-guided, 40 mL 0.25% bupivacaine, before GA induction.
QIPB is a facial plane block performed under ultrasound guidance with local anesthetic in the interfascial plane between the erector spinae and the quadratus lumborum muscle, at the distal attachment site of the quadratus lumborum muscle on the iliac crest. Single-shot, US-guided, 40 mL 0.25% bupivacaine, before GA induction.
Eligibility Criteria
You may qualify if:
- Adults aged 18-75 years
- Scheduled for elective primary total hip arthroplasty
- ASA physical status I-III
- Able to understand and communicate in Turkish and complete assessment scales
- Completed preoperative anesthesia evaluation and approved for surgery
- Signed written informed consent
You may not qualify if:
- Known allergy/contraindication to any local anesthetic, including bupivacaine
- Coagulopathy or anticoagulant/antiplatelet therapy contraindicating block (per ASRA 2022)
- Active infection or skin breakdown at the block site
- Chronic opioid use (≥3 months daily) or history of opioid dependence
- Morbid obesity (BMI \> 40 kg/m²)
- Cognitive impairment or communication difficulty precluding reliable NRS/QoR-15 assessment
- Pregnancy or breastfeeding
- Revision THA or emergency THA for fracture
- Intraoperative complications requiring major protocol deviation (e.g., \>1000 mL blood loss, cardiac arrest)
- Technically failed block (no sensory change at any region on the T1 cold test)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Dokuz Eylül University
Izmir, Balçova, 35340, Turkey (Türkiye)
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Onur Küçük, associate professor
Dokuz Eylul University
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- OTHER
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor
Study Record Dates
First Submitted
June 23, 2026
First Posted
July 6, 2026
Study Start
June 30, 2026
Primary Completion (Estimated)
December 1, 2026
Study Completion (Estimated)
June 1, 2027
Last Updated
July 6, 2026
Record last verified: 2026-06
Data Sharing
- IPD Sharing
- Will not share